Next report date
Report period
Q1 2024
EPS estimate
2.84DKK
Revenue estimate
1.10 BDKK
19.10DKK
1.48 BDKK
7.06 BDKK
77.68 M
About BAVARIAN NORDIC A/S
Sector
CEO
Paul Chaplin
Headquarters
Hellerup
Website
Employees (FY)
1.38 K
Founded
1992
ISIN
DK0015998017
FIGI
BBG000PTXZ31
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
critical point herelet us se what happens here. The company has finansed it's pipelines and have also good thing in pipeline beside the selling of its vaccines.
Monkey Pox vaxBeen tracking cdc data on monkey pox from 1st week of may this year. Cases have gone from 7 to 22k+ today. Their can be much speculation as to why or what this actually will be, but that would be another website. Bavarian Nordic has already received the green light from US and EU to mass produce the
BAVA: Monkey Pox Pharma Inverse on Bullish NewsThis accompany has just opened a contract with US and EU markets for 800k dose for Monkey POX in the US. Inverse printing. When Moderna received a contract for COIVD is 4x'd. I cant see why this wouldn't at least pump another 40% to the 1.618
Monkeypox Vaccine about to break year downtrend?Now in 30 countries and just found in India UK ordering directly from the company and earnings at the end of August
Pandemic 2.0This is not financial advice and any information that you take and act upon is at your sole discretion.
History doesn't repeat itself, but if often rhymes. If the saying holds true then Bavarian Nordic (BAVA) stands to see a great increase in it's stock price.
Listen to the video for a rundown o
$BVNRY PTs 300-400 and higher Bavarian Nordic is the only company with an FDA approved Monkey Pox Vaccine
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human
BAVA MonkeyPox VaccineHere we go again...?
"The spread of monkeypox boosted the shares of Bavarian Nordic A/S, which says it’s the only company to make a vaccine approved for the viral infection.
The Danish company gained as much as 26% in Copenhagen trading on Thursday after saying it had secured a contract to supply
Failed to break previous topBreakouts start a long period of retracement.
5 days breakout, leads to 148 days down periode.
21 days breakout leads to 59 days down periode (Currently ongoing).
Failed to break last top and got rejected.
BAVA: a great entrance pointBAVA is moving up in a channel looking at the chart back to april 2020. At the moment it is moving downwards inside this channel, and I think it will continue down below 280 Dkr. But to do so, it needs to break through and downwards from the wedge it is at presently. If it continues below 280 Dkr, i
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange BAVARIAN NORDIC A/S stocks are traded under the ticker BAVAC.
BAVARIAN NORDIC A/S is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
BAVAC earnings for the last quarter are −4.40 DKK per share, whereas the estimation was 5.87 DKK resulting in a −175.00% surprise. The estimated earnings for the next quarter are 9.08 DKK per share. See more details about BAVARIAN NORDIC A/S earnings.
BAVARIAN NORDIC A/S revenue for the last quarter amounts to 1.38 B DKK despite the estimated figure of 1.78 B DKK. In the next quarter revenue is expected to reach 2.36 B DKK.
Yes, you can track BAVARIAN NORDIC A/S financials in yearly and quarterly reports right on TradingView.
BAVAC net income for the last quarter is 901.39 M DKK, while the quarter before that showed −340.65 M DKK of net income which accounts for 364.61% change. Track more BAVARIAN NORDIC A/S financial stats to get the full picture.
No, BAVAC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BAVAC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BAVARIAN NORDIC A/S stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 1.38 K employees. See our rating of the largest employees — is BAVARIAN NORDIC A/S on this list?
We've gathered analysts' opinions on BAVARIAN NORDIC A/S future price: according to them, BAVAC price has a max estimate of 345.00 DKK and a min estimate of 170.00 DKK. Read a more detailed BAVARIAN NORDIC A/S forecast: see what analysts think of BAVARIAN NORDIC A/S and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BAVARIAN NORDIC A/S EBITDA is 2.05 B DKK, and current EBITDA margin is 29.07%. See more stats in BAVARIAN NORDIC A/S financial statements.